Compare AbCellera Biologics Inc (ABCL) vs AST SpaceMobile Inc (ASTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs AST SpaceMobile Inc — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while AST SpaceMobile Inc trades at $73.77 (market cap $22.17B). The key difference: AST SpaceMobile Inc is far larger — about 9.4× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, AST SpaceMobile Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | ASTS | |
|---|---|---|
Market Cap | $2.35B | $22.17B |
Sector | Health | Media |
52-Week High | $8.12 | $133.09 |
52-Week Low | $2.78 | $36.91 |
Enterprise Value | $1.99B | $22.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
AST SpaceMobile (ASTS) trades at $74.21, down 12.83% in the last session amid a broader space stock selloff. The stock shows bearish technical signals with negative earnings surprises and deeply negative profitability margins. Recent news highlights satellite launch progress and competitive pressures from SpaceX, while cash flow remains heavily dependent on financing activities to fund operations and capital expenditures.
Outlook remains speculative with high execution risk; revenue growth is overshadowed by persistent losses and cash burn. Analyst consensus is mixed with a $84 price target offering potential upside, but investors face significant dilution risk and competitive threats in the nascent satellite broadband market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Read more on ASTS →
